PLx Pharma Inc, a late-stage specialty pharmaceutical company, focuses on developing its PLxGuard delivery system to provide various products in the United States. The company's lead product candidates are Vazalore 325 mg and Vazalore 81 mg, which are formulations of aspirin that use the PLxGuard delivery system to reduce acute gastrointestinal (GI) side effects while providing antiplatelet effectiveness for cardiovascular disease prevention.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone713-842-1249
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$750,000.00
Profitability
Miscellaneous
Employees12
Next Earnings Date11/8/2019 (Estimated)
OptionableNot Optionable
PLx Pharma (NASDAQ:PLXP) Frequently Asked Questions
What is PLx Pharma's stock symbol?
PLx Pharma trades on the NASDAQ under the ticker symbol "PLXP."
How were PLx Pharma's earnings last quarter?
PLx Pharma Inc (NASDAQ:PLXP) released its quarterly earnings data on Friday, August, 9th. The biotechnology company reported ($0.49) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.44) by $0.05. The biotechnology company earned $0.18 million during the quarter, compared to analyst estimates of $0.33 million. PLx Pharma had a negative net margin of 2,056.16% and a negative return on equity of 25.43%. View PLx Pharma's Earnings History.
When is PLx Pharma's next earnings date?
What is the consensus analysts' recommendation for PLx Pharma?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PLx Pharma in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for PLx Pharma.
Has PLx Pharma been receiving favorable news coverage?
Press coverage about PLXP stock has trended negative on Monday, according to InfoTrie. InfoTrie rates the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. PLx Pharma earned a news sentiment score of -2.3 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for PLx Pharma.
Who are some of PLx Pharma's key competitors?
Some companies that are related to PLx Pharma include Kamada (KMDA), Five Prime Therapeutics (FPRX), Calithera Biosciences (CALA), Chiasma (CHMA), PhaseBio Pharmaceuticals (PHAS), Athersys (ATHX), Seres Therapeutics (MCRB), Evelo Biosciences (EVLO), Ocular Therapeutix (OCUL), MannKind (MNKD), Galectin Therapeutics (GALT), Cue Biopharma (CUE), Molecular Templates (MTEM), AcelRx Pharmaceuticals (ACRX) and Spero Therapeutics (SPRO).
What other stocks do shareholders of PLx Pharma own?
Who are PLx Pharma's key executives?
PLx Pharma's management team includes the folowing people:
- Mr. Michael J. Valentino, Exec. Chairman (Age 65)
- Ms. Natasha Giordano, CEO, Pres & Director (Age 59)
- Mr. Gary L. Mossman, Sr. Advisor (Age 78)
- Mr. Ronald R. Zimmerman, Founder & Sr. Advisor (Age 66)
- Ms. Rita M. O'Connor CPA, Chief Financial Officer (Age 51)
When did PLx Pharma IPO?
(PLXP) raised $68 million in an initial public offering on Thursday, February 4th 2016. The company issued 3,800,000 shares at $17.00-$19.00 per share. Raymond James served as the underwriter for the IPO and Maxim Group LLC and Janney Montgomery Scott were co-managers.
Who are PLx Pharma's major shareholders?
PLx Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (1.64%), Renaissance Technologies LLC (0.73%), Nottingham Advisors Inc. (0.66%) and BlackRock Inc. (0.11%). Company insiders that own PLx Pharma stock include Michael J Valentino and Park West Asset Management Llc. View Institutional Ownership Trends for PLx Pharma.
Which major investors are buying PLx Pharma stock?
PLXP stock was acquired by a variety of institutional investors in the last quarter, including Nottingham Advisors Inc., Vanguard Group Inc., Renaissance Technologies LLC and BlackRock Inc.. Company insiders that have bought PLx Pharma stock in the last two years include Michael J Valentino and Park West Asset Management Llc. View Insider Buying and Selling for PLx Pharma.
How do I buy shares of PLx Pharma?
Shares of PLXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is PLx Pharma's stock price today?
One share of PLXP stock can currently be purchased for approximately $5.87.
How big of a company is PLx Pharma?
PLx Pharma has a market capitalization of $53.09 million and generates $750,000.00 in revenue each year. The biotechnology company earns $900,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. PLx Pharma employs 12 workers across the globe.View Additional Information About PLx Pharma.
What is PLx Pharma's official website?
How can I contact PLx Pharma?
PLx Pharma's mailing address is 8285 EL RIO STREET SUITE 130, HOUSTON TX, 77054. The biotechnology company can be reached via phone at 713-842-1249 or via email at [email protected]
MarketBeat Community Rating for PLx Pharma (NASDAQ PLXP)
MarketBeat's community ratings are surveys of what our community members think about PLx Pharma and other stocks. Vote "Outperform" if you believe PLXP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PLXP will underperform the S&P 500 over the long term. You may vote once every thirty days.
